The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies
The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies
复制标题
DOI：
10.1016/j.breast.2006.09.003
复制
发表时间：
2007-02-01
期刊：
影响因子：
3.9
通讯作者：
Cobteigh, Melody
中科院分区：
文献类型：
--
作者：
Siziopikou, Kalliopi P.;Cobteigh, Melody
最近对乳腺癌生长和进展的分子基础的理解导致了具有潜在不同生物学行为的肿瘤亚型的鉴定。此外，靶向治疗在癌症治疗中越来越成功。我们最近报道，大多数ER阴性/PR阴性/HER 2阴性患者表达EGFR，这对肿瘤学家提出了治疗挑战。我们现在报告，这些患者中的大多数表达细胞角蛋白CK 5/6，因此属于基底亚型的乳腺癌。这些基底亚型病变通常是具有高增殖率的导管组织学高级别肿瘤。我们认为，大多数的“三阴性”患者的基底亚型肿瘤EGFR表达高，这些肿瘤可能是乳腺癌的亚组，可能受益于新的EGFR靶向治疗策略。(c)2006爱思唯尔有限公司保留所有权利。
The recent understanding of the molecular basis of breast cancer growth and progression led to the identification of tumor subtypes with potentially different biologic behavior. In addition, targeted therapies are increasingly successful in cancer treatment. We recently reported that most of the ER-negative/PR-negative/HER2-negative patients, a group that presents a therapeutic challenge for the oncologist, express EGFR. We now report that the majority of these patients express cytokeratin CK5/6 and therefore belong to the basal subtype of breast carcinomas. These basal subtype lesions are usually high-grade tumors of ductal histology with a high proliferation rate. We propose that the majority of the "triple negative" patients have basal subtype tumors with high EGFR expression and that these tumors may be the subgroup of breast carcinomas that could potentially benefit the most from novel EGFR-targeted therapeutic strategies. (c) 2006 Elsevier Ltd. All rights reserved.